VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

09 5 2024 04:00:01 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

01 5 2024 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

24 4 2024 23:00:00 提供 Nasdaq GlobeNewswire

Andrew Fisher Joins Verona Pharma as General Counsel

03 3 2024 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

28 2 2024 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

14 2 2024 23:00:00 提供 Nasdaq GlobeNewswire

Michael Austwick Joins Verona Pharma as Non-Executive Director

31 1 2024 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 1 2024 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

01 1 2024 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

16 11 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces November 2023 Investor Conference Participation

07 11 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

02 11 2023 00:04:23 提供 Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

18 10 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

05 10 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

02 10 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

10 9 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

05 9 2023 23:00:00 提供 Nasdaq GlobeNewswire

Christina Ackermann Joins Verona Pharma as Non-Executive Director

30 8 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

02 8 2023 23:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

25 7 2023 23:00:00 提供 Nasdaq GlobeNewswire